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Abstract 
Idiopathic inflammatory myopathies represent a heterogeneous group of autoimmune diseases with systemic 
involvement. Even though numerous specific autoantibodies have been recognized, they have not been included, 
with the only exception of anti-Jo-1, into the 2017 Classification Criteria, thus perpetuating a clinical-serologic gap. 
The lack of homogeneous grouping based on the antibody profile deeply impacts the diagnostic approach, thera-
peutic choices and prognostic stratification of these patients. This review is intended to highlight the comprehensive 
scenario regarding myositis-related autoantibodies, from the molecular characterization and biological significance 
to target antigens, from the detection tools, with a special focus on immunofluorescence patterns on HEp-2 cells, to 
their relative prevalence and ethnic diversity, from the clinical presentation to prognosis. If, on the one hand, a notable 
body of literature is present, on the other data are fragmented, retrospectively based and collected from small case 
series, so that they do not sufficiently support the decision-making process (i.e. therapeutic approach) into the clinics.
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Background
The detection of autoantibodies in autoimmune diseases, 
either systemic or organ specific, can have both diagnos-
tic and prognostic importance. Some autoantibodies have 
a clear pathogenic role, such as anti-erythrocyte mem-
brane proteins antibodies in autoimmune hemolytic ane-
mia and anti-dsDNA in Systemic Lupus Erythematosus 
(SLE). However, the presence of autoantibodies is more 
frequently considered to be an epiphenomenon, even 
though their detection plays a critical role for the diagno-
sis of some connective tissue diseases (CTDs), [i.e. anti-
SSA/Ro in Sjögren syndrome (SjS) and anti-Sm in SLE], 
as included into the classification criteria of CTDs [1, 2]. 
Repeated serum sampling might be informative about 
the clinical course of the disease and response to immu-
nosuppressive therapy, as in the case of anti-dsDNA 
antibodies in SLE. Furthermore, the presence of some 
autoantibodies could help to discriminate specific clinical 
patterns within the same disease, as with diffuse and lim-
ited cutaneous systemic sclerosis (SSc) and their relation-
ship with anti-Scl-70 and anti-centromere, respectively.
In idiopathic inflammatory myopathies (IIMs), albeit 
anti-Jo-1 autoantibody was discovered more than thirty 
years ago, the percentage of patients in whom an autoan-
tibody could not be recognized (the so called “serologic 
gap”) was still high until recently. IIMs have been his-
torically divided in polymyositis (PM) and dermatomy-
ositis (DM) on a purely clinical basis despite phenotypic 
variability.
Due to this heterogeneity, the numerous autoantibod-
ies and unavailability of reliable assays in all the labo-
ratories, the clinical use of serology lagged behind and 
autoantibodies are not part of the most recent IIM Clas-
sification Criteria [3].
A comprehensive review regarding the clinical features, 
diagnostic work-up and relationship to some peculiar 
autoantibodies has been recently published by Milone 
[4].
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Myositis‑specific and –associated autoantibodies: 
definitions
Autoantibodies found in IIM patients have been classi-
fied into two main categories: myositis-specific autoanti-
bodies (MSAs), which can be found in IIMs exclusively, 
and myositis-associated autoantibodies (MAAs), which 
can also be found in other CTDs [5, 6]. MSAs and MAAs 
are summarized in Table 1.
There is no agreement about the attribution of rare 
and newly discovered autoantibodies to either MSAs or 
MAAs group [7]. Anti-synthetase autoantibodies (ARS) 
themselves, especially anti-PL-7, PL-12 and KS, often 
detected in interstitial pneumonia with autoimmune 
features (IPAF) patients, independently from muscular 
involvement, are still discussed as MSAs [8].
The MAAs group contains Anti-Pm-Scl, U1/U2RNP 
and Ku, which are associated with overlap syndromes 
with muscular involvement [9]. Anti-fibrillarin and anti-
U1-snRNP are sometimes considered as MAAs, even 
though they are more specific for the diagnosis of SSc 
and mixed connective tissue disease (MCTD), respec-
tively [10, 11]. Anti-Ro52 are usually considered a MAA, 
even though they are more frequently found in associa-
tion with other MSA (ARS, anti-MDA5 and anti-SRP, in 
particular) [12], and define a peculiar clinical spectrum 
in which the lung involvement is more common than the 
muscular one [13].
Detection methods
There are several methods to test for MSAs and MAAs, 
with variable sensibility, specificity, costs, complexity 
and feasibility in clinical and research settings. Indirect 
immuno-fluorescence (IIF) on HEp-2 cells, counter-
immuno-electrophoresis (CIE), immuno-diffusion (ID) 
and immuno-enzymatic assays such as enzyme-linked 
immunosorbent assay (ELISA), fluorescent enzyme-
linked assay (FEIA) and chemiluminescent immuno-
assay (CLIA) are the most commonly adopted systems 
in diagnostic laboratories. However, immuno-precipita-
tion (IP) of RNAs with silver staining and/or protein IP 
of cellular lysates (usually K562 cells) radiolabeled with 
35S-methionin, is the gold standard for most antibodies. 
In order to streamline the detection of many autoanti-
bodies at the same time in a cost/effective manner, recent 
multiplex assays, like immunoblots (IB) and Addressable 
Laser Beads Immuno Assay (ALBIA) have been devel-
oped [14].
Anti-nuclear autoantibodies (ANA) determination by 
IIF is virtually universally available and it can be consid-
ered an accessible screening method for many MSAs and 
MAAs [15]. Furthermore, the recognition of particular 
IIF patterns can hint to some specific autoantibodies. 
However, using ANA IIF as the sole screening method 
for MSAs/MAAs, is not recommended because of low 
sensitivity, very low specificity and/or lack of antigen 
expression by HEp-2 cells [16]. In addition to this, ANA 
IIF is burdened by reproducibility issues due to the oper-
ator-dependent recognition of rare patterns and variation 
among different commercial HEp-2 substrates [17].
CIE and ID have historically been the first methods 
to detect specific MSAs/MAAs. Even though they iden-
tify numerous specificities within a single assay, they are 
semi-quantitative, work-intensive and scarcely sensitive 
[14]. For all those reasons, they have been largely substi-
tuted by immunoenzymatic tests.
The main advantages of ELISAs are standardization, 
large-scale reproducibility and quantitative results. The 
disadvantage of the conjugation of antigens to a substrate 
resides on the possible loss of conformational epitopes 
and/or the formation of neo-epitopes, which may in turn 
impact the test performance [14].
Immunoblot (IB) assays can simultaneously test for 
many autoantibodies, albeit the denaturation of proteins 
during gel preparation implicates the recognition of lin-
ear epitopes only [14].
Commercial multiplex IBs, like dot blots or line blot 
assays (LIA), based on recombinant or synthetic peptides 
have been increasingly available, benefitting from pure 
antigens not requiring a gel passage [18, 19].
IP is the gold standard as it evaluates the binding of 
the autoantibodies to the RNA and protein complexes 
in their native conformation, yielding the best sensitiv-
ity and specificity [20]. The major limitations of IP are 
due to technical difficulties, costs and use of radioactive 
reagents [20]. In addition, interpretation may be com-
plex because the target antigen can co-precipitate with 
non-target complexed proteins, with the consequence 
of multiple IP bands [20]. Thus, a comparison with ref-
erence sera or further purification and characterization 
with other methods (i.e. mass spectrometry) is necessary 
[14]. Quantitative PCR of reverse transcribed RNA com-
ponents extracted from standard IP can be also used as a 
detection method for autoantibodies binding ribonucleo-
proteic complexes [21].
Myositis‑specific autoantibodies
Anti‑synthetases autoantibodies
ARS are a group of autoantibodies directed against the 
aminoacyl transfer RNA (tRNA) synthetases, which are 
amino acid-charging enzymes. Autoantibodies to eight 
tRNA synthetases have been discovered so far: histidyl 
(Jo-1), threonyl (PL-7), alanyl (PL-12), glycyl (EJ), iso-
leucyl (OJ), asparaginyl (KS), phenylalanyl (ZO), and 
tyrosyl (YRS/HA) tRNA synthetases [22].
Anti-Jo-1 antibodies were identified by double 
immune-diffusion (DID) of calf thymus extract in 1980 
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Table 1 Summary of the main features of MSAs and MAAs
Antibody Antigen IP IIF Clinical association
Proteins (kDa) RNA HEp‑2
Myositis-specific autoantibodies (MSAs)
 Anti-Jo-1 Histidyl-tRNA syn-
thetase
50 tRNAHis Cytoplasmic fine 
speckled
Classic anti-synthetase 
syndrome with more 
frequent muscle 
involvement
 Anti-PL-7 Threonyl-tRNA syn-
thetase
80 tRNAThr Cytoplasmic dense fine 
speckled
Anti-synthetase syn-
drome with prevalent 
ILD
 Anti-PL-12 Alanyl-tRNA synthetase 110 tRNAAla Cytoplasmic dense fine 
speckled
Anti-synthetase syn-
drome with prevalent 
ILD
 Anti-EJ Glycyl-tRNA synthetase 75 tRNAGly Cytoplasmic speckled Anti-synthetase syn-
drome
 Anti-OJ Isoleucyl-tRNA syn-
thetase
150 + 170/130/75 tRNAIso Cytoplasmic speckled ILD alone or anti-syn-
thetase syndrome
 Anti-KS Asparaginyl-tRNA 
synthetase
65 tRNAAsp Cytoplasmic speckled ILD alone or anti-syn-
thetase syndrome
 Anti-Zo Phenylalanyl-tRNA 
synthetase
60/70 tRNAPhe Cytoplasmic speckled Myositis
 Anti-YRS/HA Tyrosyl-tRNA synthetase 59 tRNATyr Cytoplasmic speckled Myositis
 Anti-Mi-2 Nucleosome Remod-
elling Deacetylase 
(NuRD) (Mi-2α/β)
240 + 200/150/75/65/63/50/34 Fine speckled Classical DM
 Anti-SAE Small ubiquitin-like 
modifier activating 
enzyme (SAE1/2)
40/90 Fine speckled Severe cutaneous disease 
that classically precede 
DM with severe dys-
phagia and systemic 
symptoms
 Anti-MDA5 (anti-
CADM140)
Melanoma Differentia-
tion-Associated gene 
5 (MDA5)
140 Negative or Cytoplas-
mic speckled
Hypo-amyopathic, ILD 
with possible RP-ILD 
and severe and peculiar 
skin involvement
 Anti-TIF1γ/α (anti-
p155/p140)
Transcription intermedi-
ary factor 1 (TIF1γ/α)
155/140 Fine speckled Juvenile DM. Cancer-
associated hypo-myo-
pathic DM
Anti-TIF1β Transcription intermedi-
ary factor 1β
120 Fine speckled DM
 Anti-NXP2 (anti-MJ) Nuclear matrix protein 
(NXP-2)
140 Fine speckled and/or 
multiple nuclear dots
Juvenile DM, diffused 
calcinosis. Cancer-
associated DM
 Anti-SRP Signal recognition 
particle
72/68/54/19/14/9 7SL Cytoplasmic dense fine 
speckled
IMNM with frequent 
esophageal involve-
ment. Possible ILD
 Anti-HMGCR HMG-CoA reductase 200/100 Negative or Cytoplas-
mic speckled
IMNM with or with-
out history of statin 
exposure
Myositis-associated autoantibodies(MAAs)
 Anti-PM-Scl Exosome protein com-
plex (PM/Scl75/100)
75/100 Nucleolar homogene-
ous
Overlap PM/SSc
 Anti-C1D Exosome associated 
protein
Overlap PM/SSc
 Anti-U1-RNP U1 small nuclear RNP 11–70 U1 Coarse speckled MCTD
 Anti-fibrillarin (anti-
U3-snRNP)
Fibrillarin 34 U3 Nucleolar clumpy SSc
 Anti-Ku DNA-PK regulatory 
subunit
70/80 Fine speckled PM/SSc. Potentially 
severe ILD
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and were the first MSAs described [23]. IP represents the 
gold standard for their identification with the following 
protein bands: Jo-1 50 kDa, PL-7 80 kDa, PL-12 110 kDa, 
EJ 75 kDa, OJ 150 kDa and a multi-enzyme complex of 
170, 130, and 75 kDa, KS 65 kDa, ZO 60/70 kDa, YRS/
HA 59 kDa [22].
IIF on HEp-2 cells usually demonstrates a cytoplasmic 
pattern, ranging from fine (Jo-1) to dense fine speckled 
or homogeneous (PL-7, PL-12) whereas the nucleo-
plasm is usually negative (Fig. 1a–e) [24]. In these cases, 
also patients without muscular involvement should be 
assessed for ARS especially when interstitial lung dis-
ease (ILD), arthritis or scleroderma features are present 
[25].
Anti-Jo-1 is the only autoantibody routinely tested 
as widely available in most commercial ENA screening 
assays. An ELISA screening test has been recently devel-
oped to identify ARS, with high sensibility and specificity 
if compared to IP [26] and some commercially available 
IBs can identify some non-Jo-1 anti-synthetase antibod-
ies [20, 25].
Anti-Jo-1 was first discovered in the ‘80ies in patients 
with PM [23]. Larger cohorts later demonstrated that 
its presence was associated with the classical triad of 
arthritis, myositis and ILD in the majority of patients, 
in addition to Raynaud’s phenomenon, mechanic’s 
hands and fever. This clinical presentation together with 
anti-Jo-1 autoantibodies, led to the description of the 
Table 1 continued
Antibody Antigen IP IIF Clinical association
Proteins (kDa) RNA HEp‑2
 Anti-Ro52 Ro-52/TRIM21 52 Negative, fine speckled 
or cytoplasmic 
speckled
ILD. Frequently coupled 
with other MSA
 Anti-Ro60/SSA Ro-60/SS-A 60 Fine speckled SjS, SLE
 Anti-La/SSB SS-B 48 Fine speckled SjS, SLE
 Anti-cN-1A (anti-
Mup44)
Cytosolic 5′nucleoti-
dase 1A
sIBM
Miscellaneous
 Anti-RuvBL1/2 RuvBL1/2 complex 48/49 Speckled SSc, PM, Morphea
 Anti-Su/Ago2 Argonaute 2 100/102 and 200 Cytoplasmic discrete 
dots
ILD in absence of cancer. 
Frequently coupled 
with MSA, Ro-52 and 
other antibodies
 Anti-SMN Survival of Motor 
Neuron
38 + 130/120/33 Few nuclear dots PM/SSc
 Anti-NUP Nup358/RanBP2, gp210, 
Nup90, p200/p130, 
Nup62
Punctate nuclear 
envelope
Subgroup of PM/SSc 
patients (so called NUP-
syndrome). PBC
 Anti-mitochondrial 
(AMA-M2)
Branched-chain 
α-ketoacid dehydro-
genase complex
Cytoplasmic reticular/
AMA
Long-lasting myositis 
with muscle atrophy 
and cardiac involve-
ment. PBC
 Anti-KJ Translocation factor 30/43 Cytoplasmic speckled Anti-synthetase-like 
syndrome
 Anti-Fer (anti-eEF1) Eukaryotic elongation 
factor 1
Anti-synthetase-like 
syndrome
 Anti-Wa 48 Cytoplasmic speckled Anti-synthetase-like 
syndrome
 Anti-Mas selenocysteine seryl-
tRNA-protein complex
48 tRNA[Ser]Sec Cytoplasmic speckled Non-immune mediated 
rhabdomyolysis. Auto-
immune hepatitis
 Anti-PMS DNA repair mismatch 
enzyme (PMS1, PMS2, 
MLH1)
Mild myositis
 Anti-cortactin Cortactin 68 PM. Myasthenia gravis
 Anti-FHL1 Four-and-a-Half LIM 
domain 1
Myositis and muscular 
atrophy with severe 
systemic involvement
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antisynthetase syndrome (ASSD), the first attempt to 
phenotype IIMs in clinical-serologic syndromes [27]. 
Anti-Jo-1 is detected in 15-25% of patients with poly-
myositis/dermatomyositis (PM/DM), whereas the other 
ARS are rarer (anti-PL-7 4-12%, PL-12  <  5%, EJ  <  5%, 
OJ  <  5% and only few cases reported with anti-KS, ZO 
e HA/YRS) [22]. In two-third of the cases, high titers of 
anti-Ro52 antibodies can be also detected and have been 
associated with an higher risk of ILD [28].
Clinically, anti-PL-7 patients more frequently present 
hypo-myopathic features [29, 30], whereas in anti-PL-12 
and anti-KS patients the disease can be limited to the 
lung [31–33]. In a quarter of anti-Jo-1 patients, a sym-
metrical polyarthritis mimicking rheumatoid arthritis is 
the main presenting finding and, in some of them, anti-
cyclic citrullinated peptide antibodies and rheumatoid 
factors can be also detected [34].
Regardless of clinical characteristics at presenta-
tion (arthritis, myositis and ILD) every patient tends to 
develop the other features of ASSD when not properly 
treated [34]. Of note, the lower esophageal sphincter is 
involved more frequently if compared to the other IIMs 
[35]. ASSD is histopathologically classified within per-
imysial immune-myopathies in which perimysium frag-
mentation and muscle fiber necrosis are the main feature, 
differently from other DM biopsically characterized by 
atrophy and vasculopathy [36]. Type I interferon-signa-
ture in ASSD is responsible for MHC class I upregulation 
[37] and MHC class II perifascicular expression [38].
Anti‑Mi‑2
Anti-Mi-2 antibodies were the first autoantibodies spe-
cific for DM recognized by DID using calf thymus extract 
[39]. Mi-2 is a helicase of the Nucleosome Remodeling 
Fig. 1 IIF on HEp-2 ANA slides of myositis-specific autoantibodies from patients with IIMs (EUROIMMUN, Lübeck, Germany). a Anti-Jo-1 and b 
anti-Jo-1 and anti-Ro52, c anti-PL-7, d anti-PL-12, e anti-KS, f anti-Mi-2, g anti-SAE-1, h anti-MDA5, i anti-NXP-2 and j anti-NXP-2 with coiled bodies, k 
anti-TIF1γ, l anti-SRP
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Deacetylase (NuRD) multi-protein complex with nucleo-
some remodeling and histone deacetylase/demethylase 
activities [40]. Anti-Mi-2 autoantibodies immunopre-
cipitate a major protein of 240  kDa, composed by two 
proteins, Mi-2α and Mi-2β of 220 and 218 kDa, respec-
tively. Other NuRD complex proteins co-precipitate at 
200, 150, 75, 65, 63, 50 and 34 kDa [41, 42]. IIF on HEp-2 
cells reveals a characteristic fine speckled ANA pattern; 
during metaphase, chromatin mass is not stained but 
the nucleoplasm presents the same fine tiny speckles 
(Fig. 1f ). Commercial ELISA and immunoblot kits iden-
tify anti-Mi-2 autoantibodies. Anti-Mi-2 are commonly 
detected in DM patients, either in adults (11–59%) or in 
children (4–10%), with a great variability among the stud-
ies. Their presence in PM and sporadic inclusion body 
myositis (sIBM) is rarer [40].
The Mi-2 protein is over-regulated during muscle 
regeneration in DM patients and thought to be related 
to UV rays exposition, sex and HLA (DRB1*0302 and 
DRB1*0701) [43–45]. Anti-Mi-2 positive DM patients 
usually exhibit mild myopathy despite high creatine 
kinase (CK) levels, without lung involvement and/or can-
cer [43]. Overall, anti-Mi2 positive is associated with a 
positive prognosis and a good response to corticosteroids 
[43].
Anti‑SAE
Small Ubiquitin-like Modifiers (SUMOs) have a key role 
in post-transcriptional modification of specific proteins 
in a ubiquitin-like fashion. This process is controlled 
by the SUMO-Activating Enzyme (SAE), a heterodi-
mer composed of two subunits, SAE-1 and SAE-2 [46], 
representing the targets of anti-SAE autoantibodies. IP 
characteristically shows two bands of 40 and 90  kDa, 
respectively [46, 47]. The IIF ANA pattern is coarse 
or fine speckled and nucleoli are typically not stained 
(Fig. 1g) [47].
Anti-SAE are associated with a typical DM phenotype 
with different prevalence in European (4-10%) and Asian 
(1–3%) cohorts [48–50], probably due to the strict asso-
ciation with HLADRB1*04-DQA1*03-DQB1*03 haplo-
types [51].
The cutaneous involvement is usually severe and typi-
cally precedes the muscular involvement. Other clini-
cal relationships cannot be excluded because of the few 
described cases. However, ILD seems to be rare, whereas 
severe dysphagia and systemic symptoms have been 
reported [47]. Only one case series claimed an associa-
tion with cancer [52].
Anti‑MDA5
Melanoma Differentiation-Associated gene 5 (MDA5) 
or Interferon-induced helicase C domain-containing 
protein 1 (IFIH1), is an innate cytosolic sensor, member 
of the retinoic acid-inducible gene I (RIG-I)-like recep-
tors family (RLRs). MDA5 is able to recognize double-
stranded RNA and to initiate signaling events leading to 
type I interferons production [53].
Anti-MDA5 autoantibodies were firstly detected in IP 
as a 140  kDa band in a Japanese case series of patients 
with clinically amyopathic dermatomyositis (CADM) and 
rapidly progressive interstitial lung disease (RP-ILD). For 
this reason, they were initially called anti-CADM-140 
autoantibodies [54]. Nowadays, ELISA and IB tests are 
commercially available.
IIF on HEp-2 cells is usually negative. In our experi-
ence, a faint fine speckled cytoplasmic fluorescence may 
be detected in scattered cells (unpublished data) (Fig. 1h).
Clinically, DM anti-MDA5 positive patients present 
low grade/absent muscle inflammation and acute or 
subacute RP-ILD [55, 56], which is considered the major 
negative prognostic factor of this subgroup [57].
MDA5 represents the most frequent target antigen in 
DM patients of Asian ancestry (10–48% of cases) [58] 
whereas its prevalence in Europe and USA ranges from 0 
to 13%, with great variability among the studies [59–61] 
and a different clinical presentation. A forthcoming Euro-
pean case series is going to be presented at the European 
League Against Rheumatism 2018 Congress by Cavagna 
et  al. (unpublished data). A seasonal pattern of CADM 
has been proposed by Muro et  al. [62], suggesting the 
influence of environmental factors and HLA-DRB1*04:01 
and *12:02 have been proposed as further predisposing 
factors [63].
In addition to classic DM-related cutaneous manifesta-
tions, skin involvement is usually severe and character-
ized by the so called “inverse Gottron papules”, which 
are tender palmar papules that tend to evolve towards 
ulcerated-necrotic lesions, with or without digital pulp 
ulcers [64, 65]. In addition, polyarthritis, recurrent oral 
aphtosis and diffuse alopecia have been described [66]. 
A juvenile DM with anti-MDA5 autoantibodies has been 
also described [67]. No association with malignancies has 
been demonstrated so far. Macrophage activation syn-
drome have been described in CADM associated RP-ILD 
patients. Particularly, a ferritin level of above 1500 ng/mL 
has been claimed as a predictor of death [68, 69]. Anti-
MDA5 autoantibodies titer seems to correlate with dis-
ease activity and response to therapy [69].
Anti‑TIF‑1
The transcription intermediary factors-1 (TIF-1) fam-
ily belongs to the tripartite motif-containing proteins 
(TRIM) superfamily and is involved in multiple biologi-
cal processes, such as cycle regulation, mitosis and innate 
immunity [70].
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Targoff et  al. and Kaji et  al. [71, 72] independently 
described two antibodies directed against a 155 and 
140  kDa, rapidly identified as TIF-1γ (TRIM33) and 
TIF-1α (TRIM24), respectively. Subsequently, a third 
120 kDa band, partially overlapping with anti-PL-12, was 
identified as TIF1β (TRIM28) [73].
IIF on HEp-2 cells demonstrates a fine speckled nuclear 
pattern (Fig. 1i). ELISA and IB, compared to IP, are reli-
able test for the detection of anti-TIF-1γ autoantibod-
ies [74]. Two-thirds of the patients present anti-TIF-1γ 
and anti-TIF-1α autoantibodies, whereas the remain-
ing one-third is positive for anti-TIF-1γ autoantibodies 
exclusively [70]. Albeit MSAs are claimed to be mutually 
exclusive, double-positive patients for anti-TIF-1α/Mi-2 
autoantibodies have been described [75].
Hyper-expression of TIF-1γ has been found in tumors 
[76] and regenerating myofibres of DM patients [77]. A 
meta-analysis demonstrated that anti-TIF-1γ has a 78% 
sensitivity and 89% specificity for the diagnosis of cancer-
associated myositis, with a 58% positive and 95% negative 
predictive value [78]. The risk of malignancy is higher 
in patients with anti-TIF-1γ/α than in those with anti-
TIF-1γ alone [70].
Clinically, anti-TIF-1 positive patients can be classified 
in two age groups: (1) younger than 40-year-old patients, 
with a classical DM at presentation and (2) older than 
40-year-old patients, with cancer-associated myositis 
[70]. Solid tumors, like ovary, lung and breast cancer are 
the most commonly associated neoplasia, but hemato-
logic disorders and malignancies have been described as 
well [79]. In general anti-TIF-1γ patients exhibit a hypo-
myopathic DM with reduced prevalence of systemic 
involvement, namely ILD, Raynaud’s phenomenon and 
arthritis [80]. Conversely, nutcracker esophagus is three 
times more frequent in anti-TIF-1γ patients than other 
IIMs [35]. Widespread cutaneous involvement is associ-
ated with unique features, such as palmar hyper-keratotic 
papules, psoriatic-like dermatitis and atrophic hypo-pig-
mented patches with telangiectasias [80]. An ovoid pal-
atal patch may be present in about one half of patients, 
more frequently females with cancer-associated amyo-
pathic disease [81].
Anti‑NXP‑2
Nuclear matrix protein 2 (NXP-2), encoded by the micro-
rchidia 3 gene, is a 140 kDa protein involved in epigenetic 
regulation, RNA metabolism and preservation of nuclear 
chromatin architecture [82]. Anti-NXP-2 autoantibod-
ies were found in a cohort of juvenile DM patients as a 
140 kDa protein firstly named anti-MJ [83].
IIF on HEp-2 cells reveals a fine speckled nuclear 
pattern (Fig.  1k). Moreover, a nuclear dots pattern is 
detectable in 60% of sera [84], due to co-localization of 
NXP-2 with pro-myelocitic leukemia (PML) bodies [85] 
(Fig. 1j).
Anti-NXP-2 antibodies have been initially associated 
with a severe juvenile DM complicated by calcinosis, 
polyarthritis and intestinal vasculitis [86]. More recently, 
they have been also found in adult patients, with variable 
prevalence from 1.6 to 17% [87–89]. Anti-NXP-2 autoan-
tibodies show a bimodal spectrum of clinical association, 
with calcinosis being more frequent in younger patients 
and cancer more common in the elderly [90], especially 
in male gender [88], even though with a lower prevalence 
when compared to anti-TIF-1 [87, 88].
Anti‑SRP
The signal recognition particle (SRP) is a complex of six 
proteins (9, 14, 19, 54, 68 and 72 kDa) and a 300 nucleo-
tides long RNA (7SL RNA) involved in the recognition 
and transportation of proteins to the endoplasmic reticu-
lum [91]. Anti-SRP autoantibodies are more frequently 
directed against the SRP-54 fragment, albeit anti-SRP-68, 
anti-SRP-72 and anti-7SL RNA autoantibodies have been 
also described [91].
A dense fine speckled cytoplasmic pattern has been 
associated with the presence of anti-SRP (Fig. 2a); more-
over, IIF on stomach–liver–kidney rat sections dem-
onstrates a cytoplasmic staining of gastric chief cells 
(Fig. 2b) and hepatocytes (Fig. 2c) [92].
Anti-SRP-54 autoantibodies ELISA tests are commer-
cially available, but they are less sensitive than IP [93]. 
Anti-SRP antibodies can also be tested on LIA assays, 
however careful temperature control is necessary in 
order to avoid false positive results [19].
These autoantibodies are strongly associated with 
immune-mediated necrotizing myositis (IMNM) where 
they may play a pathogenic role [94]. Histopathologically, 
they are characterized by scarce inflammatory CD8+ 
endomysial infiltrate, class I MHC upregulation, necro-
sis and myofiber regeneration [36] with poor response 
to therapy, mimicking muscular dystrophy [95]. Being 
strongly associated to HLA-DR5, the prevalence of anti-
SRP autoantibodies is higher in Asian (8–13%) than in 
European patients [96]. Prevalence of anti-SRP in IMNM 
is highly variable among studies, ranging from 0 to 54%, 
because of differences regarding the type of assay (IB 
vs IP), low number of patients and genetic background 
[97–100]. In addition, esophageal involvement is com-
mon [101], whereas the possibility of a prominent car-
diac involvement has not been yet confirmed [99, 102]. 
Lung involvement has been reported in a few cases 
[103], as well as an overlap with anti-synthetase anti-
bodies like PL-12 and anti-Jo-1 [104, 105]. Intriguingly, 
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autoantibodies level correlates to disease activity, CK lev-
els and response to therapy [106].
Anti‑HMGCR
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR) is the rate-controlling enzyme of the meva-
lonate pathway, bringing to the production of cholesterol. 
Of note, HMGCR is the same enzyme targeted by statins. 
Autoantibodies towards a complex 200/100  kDa band 
were first described in patients with IMNM, and only 
after identified as anti-HMGCR autoantibodies [107].
IIF pattern is difficult to recognize. In a minority of 
cases finely granular cytoplasmic staining with a peri-
nuclear reinforcement is visible on a small number of 
scattered cells (3% of the total cellularity) (Fig.  2g). On 
rat liver, a scattered cytoplasmic staining of hepatocytes 
around the liver lobules, namely anti-HMGCR Antibody 
Associated Liver Immunofluorescence Pattern (HALIP), 
can be noted (Fig. 2i) [108, 109]. Anti-HMGCR antibod-
ies can be identified with different immunoenzymatic 
technologies, such as ELISA, CLIA, IB or ALBIA [110].
A history of statin exposure is not mandatory to 
develop anti-HMGCR positive IMNM, being of some 
relevance only in patients older than 50 [111, 112]. Anti-
HMGCR antibodies are not found in self-limiting statin 
associated myopathy [113], albeit they may be associated 
with an increased risk of cancer [114]. An association 
with the DRB1*11:01 haplotype has been demonstrated, 
whereas DQA1 and DQB1 seem to have a protective role 
[115].
Anti-HMGCR positive patients present with a typical 
IMNM, responds well to immunosuppressive therapy 
Fig. 2 Immunofluorescence patterns from patients with IMNMs with anti-SRP and anti-HMGCR antibodies on HEp-2 ANA slides (EUROIMMUN, 
Lübeck, Germany) and rat liver and stomach slides (DiaSorin, Italy), compared to AMA-M2 antibodies. a Anti-SRP cytoplasmic dense fine speckled 
pattern on HEp-2, b chief cells on stomach and c fine granular liver staining; d AMA-M2 cytoplasmic reticular on HEp-2, e granular staining of 
parietal stomach cells and f diffused fluorescence of hepatocytes; g Anti-HMGCR faint cytoplasmic fluorescence on few numbers of HEp-2 cells, h 
negative stomach and i fine cytoplasmic fluorescence of scattered hepatocytes around the biliary ducts
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and intravenous immunoglobulins [116], but tend to 
relapse after tapering [111]. Younger patients experience 
more severe disease with worse prognosis [117]. Autoan-
tibody titers seem to correlate with CK levels, muscular 
weakness and response to therapy [111].
Myositis‑associated autoantibodies
Numerous MAAs have been described so far. Character-
istically, they can be found in IIMs, albeit not specific as 
found in other CTDs [118].
Anti‑PM‑Scl
Anti-PM-Scl autoantibodies are directed against the exo-
some, a macromolecular nucleolar complex composed 
by 11–16 proteins (from 20 to 110  kDa) that degrades 
mRNA. The two pivotal proteins of the complex are PM-
Scl-75 and PM-Scl-100. IP represents the gold standard 
for their determination. Historically, an ID test after posi-
tive nucleolar staining in IIF was used to confirm anti-
PM-Scl reactivity.
PM-Scl-100 and PM-Scl-75 were identified in 1992 and, 
in the following years, the immuno-dominant epitope 
PM1α was cloned and employed to develop reliable and 
specific ELISA tests [119]. PM1α ELISA and PM-Scl-100 
LIA tests show concordance with IP at high level (>  90 
and 98.3%, respectively), whereas PM-Scl-75 LIA has 
a lower specificity, especially when considering PM/
SSc overlap syndromes [120]. Single positivity against 
PM-Scl-75 or -100 can be detected and associates with 
different disease phenotypes. HEp-2 IIF typically shows a 
mixed homogeneous nucleolar and fine speckled nuclear 
pattern when anti-PM-Scl-100 are present, whilst anti-
PM1-α and PM-Scl-75 may show both nucleolar and 
non-nucleolar patterns (Fig. 3a, b).
PM-Scl autoantibodies are found in 4–12% of adult 
patients with myositis [121, 122] with low prevalence in 
Asiatic and paediatric cohorts [123]. Their presence has 
been associated with HLA-DQA1*0501, DQB1*02 and 
DRB1*0301 alleles [122].
Despite their presence in many connective tissue dis-
eases, these autoantibodies are typically present in 
PM/SSc overlap syndromes with an increased risk of 
Raynaud’s phenomenon, arthritis, mechanic’s hands and 
ILD [124]. In detail, isolated anti-PM-Scl-75 have been 
more frequently found in patients with joint contractures 
and SSc, higher CK levels associate with anti-PM-Scl-100, 
whereas the simultaneous presence of anti-PM-Scl-75 
and -100 are linked to muscle involvement, digital ulcers 
and ILD but lower prevalence of lung hypertension [125].
Autoantibodies directed against C1D, an exosome 
associated protein, were detected by ELISA and West-
ern blot analysis in 23% of a PM/SSc overlap syndrome 
cohort, with frequencies comparable to anti-PM/Scl anti-
bodies [126].
Fig. 3 Myositis-associated autoantibodies and some peculiar IIF pattern on HEp-2 ANA slides (EUROIMMUN, Lübeck, Germany). a anti-PM-Scl-100, 
b anti-PM-Scl-75, c anti-U1-snRNP, d anti-Ku, e anti-fibrillarin, f cytoplasmic discrete dots as seen in anti-Su/Ago2, g nuclear few nuclear dots as seen 
in anti-SMN, h punctate nuclear envelope as seen in anti-NUP
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Anti‑RNP
The RNP/Sm complex comprises several proteins (70 kD, 
A, A′, B, B′, B″, C, D, E, F, G) and five RNA (U1, U2, U4, 
U5 and U6). U1 RNA interacts with 70 kD, A and C to 
create the U1-snRNP [127]. High-titre anti-U1-snRNP 
and in particular when targeting the 70kD protein are 
considered specific markers of mixed connective tis-
sue disease (MTCD), whereas low titres can be found in 
other CTDs [127].
Many home-made or commercial assays can detect 
anti-RNP autoantibodies, with differences among immu-
noassays depending on the immobilized antigen [127]. 
Usually, anti-U1-snRNP (more often the 70k subunit) 
and the anti-Sm (typically the D subunit) are the only 
autoantibodies tested in clinical practice. Large speckled 
and large coarse speckled are the most frequent HEp-2 
IIF patterns observed (Fig. 3c).
Patients with myositis may exhibit anti-U1-snRNP 
positivity, especially those with a mild disease [128, 
129]. They are usually steroid-responsive, even though 
ILD and/or neurological involvement may be part of the 
clinical presentation [128, 129]. Whether the only pres-
ence of anti-U1-snRNP and myositis has to be consid-
ered an incomplete form of MTCD or a true myositis, is 
still a matter of debate [128, 129]. In addition, anti-U2-
RNP [130], U5-RNP [131] and anti-U4/U6-RNP [132] 
have been described in patients with PM/SSc overlap 
syndrome.
Anti‑fibrillarin
Fibrillarin, a highly conserved nucleolar 34  kDa protein 
involved in the processing of ribosomal RNA, is part of 
the U3-small nucleolar (sno)-RNP complex together 
with other proteins and U3 RNA. Fibrillarin is the pri-
mary target of anti-U3-snoRNP autoantibodies [133]. IP 
is the gold standard for its detection showing good con-
cordance with IB assays that use the recombinant protein 
[134].
HEp-2 IIF demonstrates a typical “clumpy” nucleolar 
pattern, with jagged staining of the nucleoli, coiled bodies 
and peri-chromosomal staining at the metaphase plates 
[135] (Fig. 3e).
Anti-fibrillarin antibodies are detected in a small 
percentage of SSc patients and rarely in SLE, primary 
Raynaud’s phenomenon and myositis [136]. In detail, 
they identify a subset of SSc patients more often of Afri-
can origin, with serious cutaneous and visceral involve-
ment and a higher prevalence of myositis [137, 138].
Anti‑Ku
The Ku protein, involved in the canonical non-homol-
ogous end-joining pathway of the DNA repair, is a het-
erodimer consisting of the two subunits, 70 and 80 kDa 
[139]. Anti-Ku can be identified with numerous assays, 
such as ELISA, CIE or IB. IIF demonstrates a fine speck-
led nuclear pattern with a peculiar ring beam surround-
ing the metaphase on HEp-2 cells and a clumpy speckled 
pattern on primate’s liver [140] (Fig. 3d).
Anti-Ku autoantibodies have been identified in 9-19% 
of the patients with PM/SSc overlap syndromes and SLE, 
being associated with arthralgia, Raynaud’s phenomenon 
and ILD [141, 142]. Of note, whilst muscular involvement 
seems to be steroid-sensitive, ILD is more frequently pro-
gressive, severe and steroid-resistant [143].
Anti‑Ro
Antibodies directed against the ribonucleoproteic com-
plex SSA/Ro and SSB/La have been originally identified 
in SjS and SLE. Actually, antigen Ro is made by two sep-
arate complexes of 52 and 60  kDa called Ro52/TRIM21 
and SSA/Ro60, respectively. Antigen SSB/La has a molec-
ular weight of 48 kDa [144].
ANA may result falsely negative on traditional HEp-2 
cells when isolate anti-Ro are present, because Ro52 is 
a cytoplasmic antigen and Ro60 may be lost during the 
preparation. For this reason, human SSA/Ro60-trans-
fected HEp-2 cells (HEp-2000) are sometimes used [145, 
146]. Otherwise, a characteristic pattern defined as “myr-
iad discrete fine speckled” may be observed [147]. Anti-
SSB autoantibodies show a similar pattern [148].
Anti-Ro52 can be found in IIMs [149] and are fre-
quently associated with other MSAs, in particular 
anti-synthetase [28], anti-MDA5 [61] and anti-SRP 
autoantibodies [12].
They are known to be a negative prognostic factor 
regarding systemic involvement such as ILD, whereas 
their role in the severity of muscular involvement has 
not been identified [13]. Anti-Ro52 autoantibodies are 
known to be associated with atrioventricular congenital 
heart block [150].
Anti‑cN‑1A
Cytosolic 5′nucleotidase 1A (cN-1A o NT5C1A) 
is a protein involved in the hydrolysis of adenosine 
monophosphate, controlling energy and metabolic cell 
balance [151]. Anti-cN-1A autoantibodies, first called 
anti-Mup44, were simultaneously described by Sala-
jegheh et  al. and Pluk et  al. [152, 153] as targeting a 
44 kDa protein in patients with sIBM.
These autoantibodies were initially detected by immu-
noblotting from purified skeletal muscle extracts [153]. 
A novel standardized IgG ELISA is now available [154]. 
In addition to IgG, circulating IgA and IgM anti-cN-1A 
autoantibodies have been recognized [155]. IIF ANA pat-
tern is still undefined.
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Anti-cN-1A autoantibodies are demonstrated in one-
third of the patients with sIBM and in less than 5% with 
other IIMs or neuromuscular diseases [151]. A recent 
study demonstrated that positive anti-cN-1A sIBM 
patients are included in a more severe sIBM subtype and 
represent a homogeneous group as exhibiting higher 
mortality risk, less proximal upper limb weakness (not 
typical of sIBMs) and a cytochrome oxidase deficiency 
in muscular fibers, when compared to negative patients 
[156].
It is not known whether they have to be considered as 
MSAs or MAAs as also demonstrated in other autoim-
mune diseases, such as SjS (30%) and SLE (20%) [157]. 
Furthermore, they have been recently demonstrated in a 
cohort of severe juvenile myositis with lung involvement, 
juvenile idiopathic arthritis, but also in 12% of healthy 
children [158].
Despite low sensitivity, anti-cN-1A autoantibodies are 
high specific and highly predictive of sIBM [159] thus 
being of particular importance when bioptic specimens 
are not diagnostic.
Miscellaneous autoantibodies in IIM
Several other autoantibodies have been identified as 
associated with IIMs, but little is known about their clini-
cal relevance. In fact, they are not routinely determined 
because easy-to-perform routine specific immunoassays 
still lack and they are rarely found.
Anti‑RuvBL1/2
RuvBL1 (49kD) and RuvBL2 (48kD) constitute a nuclear 
complex involved into DNA repair and transcription. 
Two distinct bands of approximately 50 kDa are found in 
IP [160]. By means of ELISA and/or IB techniques, anti-
RuvBL1/2 have been found in several CTDs, but those 
involved in SSc and myositis recognize different confor-
mational epitopes identified by IP exclusively [160]. On 
HEp-2 cells, a fine speckled pattern is associated with 
these antibodies, with increased fluorescence in prophase 
and decreased in metaphase. Additionally, a fine speckled 
pattern can be found in the cytoplasm of about 40% posi-
tive sera [160]. Anti-RuvBL1/2 antibodies are highly spe-
cific for SSc, are associated with PM/SSc overlaps with 
diffuse cutaneous sclerosis and more frequently found in 
older patients of male sex [160–162] or, less frequently, in 
necrotizing polymyositis with morphea [162].
Anti‑Su/Ago2
Anti-Su/Argonaute-2 (anti-Su/Ago2) autoantibodies 
have been originally identified in SLE patients by means 
of immunodiffusion technique in the late ‘80ies [163]. 
Although their high prevalence in CTDs, few studies are 
available.
By IP, two distinct 100 and 102  kDa adjacent bands 
can be seen in addition to a further 200 kDa band [164]. 
Argonaute-2 protein constitutes the 100  kDa band and 
plays a key role in miRNA and interference RNA matura-
tion and metabolism [163]. Argonaute-2 colocalized with 
GW bodies, a cytoplasmic organelle associated with RNA 
metabolism [164]. Its location and function is responsible 
for the particular cytoplasmic pattern of these autoanti-
bodies also known as “GW-bodies-like” or “cytoplasmic 
discrete dots” (Fig. 3f ) [164].
Anti-Su/Ago2 autoantibodies are frequently associated 
with other MSA or MAA antibodies, in particular ARS, 
anti-TIF-1γ and anti-MDA5 [165]; anti-Ro52 antibodies 
are found in almost one half of the patients [166]. It has 
been reported that anti-Su/Ago2 antibodies can be dem-
onstrated in about 7.5% of the patients of Japanese origin. 
Apparently, there is no statistical difference between anti-
Su/Ago2 positive and negative patients; however, a cor-
relation seems to exist with ILD and absence of cancers 
[165].
Anti‑SMN
The Survival of Motor Neuron (SMN) is a multi-ribo-
nucleoproteic complex able to interact with the RNP-
complex related D–E–F-G proteins. The SMN complex 
is involved into the assembly of snRNPs and co-local-
izes with Cajal bodies. These autoantibodies have been 
first described in a small number of PM patients nega-
tive for anti-U1-snRNP and/or anti-Sm but positive for 
RNP D–E–F-G bands by IP. This observation was indeed 
responsible for the identification of other SMN-com-
plex components, namely Gemin 2 (33  kDa), Gemin 3 
(130 kDa), Gemin 4 (120 kDa) and SMN itself (38 kDa) 
[167].
Anti-SMN antibodies typically exhibit a few nuclear 
dots pattern on HEp-2 cells with well distinguished 2–7 
nuclear dots, similarly to anti-p80-coilin, anti-NXP2 and 
anti-PML pattern, seldom associated to cytoplasmic or 
nuclear speckled patterns (Fig. 3g).
It is not clear whether positive patients exhibit distinct 
clinical features. Anyhow, in the original small group of 
positive patients [167] and a small Italian cohort [20], a 
PM/SSc overlap syndrome was present. It is of note that 
SMN-complex genetic mutations are frequently found 
in neuromuscular degenerative diseases such as spinal-
muscle atrophy. That is why anti-SMN autoantibodies are 
of relevance in basic research [168].
Anti‑NPC
Nuclear pore complex (NPC) regulates protein and RNA 
trafficking to the nucleus. It is constituted by a complex 
of several proteins including Nup358/RanBP2, Nup90, 
Nup62 and gp210 [169]. Anti-NPC autoantibodies, 
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and, in particular, anti gp210 are typically associated to 
Primary Biliary Cholangitis (PBC) and Autoimmune 
Hepatitis (AIH) [170]. In a cohort study from Canada, 
anti-NPC antibodies were found in a PM/SSc overlap 
syndrome and called anti-NUP Syndrome, which was 
found to be associated with HLA-DQ1*0501. In this case, 
a typical nuclear speckled laminar pattern on HEp-2 cells 
was observed [171] (Fig. 3h).
AMA‑M2
Among the ten different anti-mitochondrial antibod-
ies (AMA), called M1–M10, anti-M2 antibodies (AMA-
M2) are the hallmark of PBC [172]. However, they can be 
also found in 7–12% of IIM patients without PBC [173]. 
AMA antibodies are readily detectable on HEp-2 cells as 
they display a pathognomonic cytoplasmic reticular pat-
tern, and in triple tissue slides (Fig. 2d–f). In a Japanese 
study, the presence of AMA-M2 in the course of IIM was 
associated with muscle atrophy, granuloma formation 
[173] and heart involvement with high risk of supraven-
tricular arrhythmias [174]. A distinct inflammatory phe-
notype associated with chronic skeletal muscle disease 
and severe cardiac involvement was also found in a North 
American cohort [175]. These associations have not been 
confirmed in an European series [176].
Other antibodies
Several cytoplasmic autoantibodies are described in IIM 
patients such as anti-KJ towards a 30/43 kDa transloca-
tion factor [177], anti-Fer directed against the elongation 
factor 1 and anti-Wa recognizing a 48  kDa cytoplasmic 
protein with still unknown function [132]. All these 
antibodies are typically found in anti-synthetase-like 
syndromes. Anti-Mas antibodies are directed against a 
selenocysteine-containing tRNA complex lacking any 
tRNA-synthetase activity but involved in protein trans-
location. The band of precipitation is found at 48  kDa 
[178]. These antibodies have been described in AIH and 
in a single patient with non-immune mediated rhabdo-
myolysis [178].
DNA-repairing complexes, especially mismatch-
repair complexes such as PMS1, PMS2 and MLH1, are 
frequently recognized as target antigens in IIMs [179]. 
Initially defined as MSAs, they do indeed frequently 
associate with other MSAs, in particular anti-Mi-2, but 
they can also be found in other non-muscular diseases, 
such as SLE. They generally mark mild disease [180].
Anti-cortactin antibodies have been initially found in 
IIM patients characterized by the simultaneous pres-
ence of anti-MDA5 or anti-HMGCR antibodies by ELISA 
[181]. As blot confirming assay identified an unexpected 
68 kDa band, it was then found that MDA5 and HMGCR 
extracts used in the ELISA tests were contaminated by 
cortactin [181]. Anti-cortactin antibodies were originally 
found in myasthenia gravis [182] and later in IIM patients 
(about 20%) and other systemic connective tissue dis-
eases [181].
Anti-Four-and-a-Half LIM domain 1 (FHL1) antibod-
ies were identified in about 25% of IIM patients. These 
antibodies associated with a severe prognosis, muscle 
atrophy, vasculitis, dysphagia and advanced muscular 
damage. Curiously, FHL1 mutations cause hereditary 
X-linked congenital myopathies [183].
Conclusions
Although autoantibodies are considered to be epiphe-
nomenon in autoimmunity, their presence frequently 
plays a pivotal role for the diagnosis of these diseases. 
Indeed, several of them exhibit a pathogenethic role in 
IIMs. Despite this, there is still a gap between bench and 
bedside because the intense basic research efforts have 
not been translated in clinical practice, as already futur-
istically underlined more than 20 years ago [96, 184]. As 
a fact, only anti-Jo-1 have been included into the 2017 
Classification Criteria for Adult and Juvenile IIMs [3].
Remarkably, in the context of heterogeneously grouped 
diseases such as myositis, they should be even more 
appreciated as able to clinically stratify patients in terms 
of diagnostic work-up, histological patterns, peculiar 
organ involvement, severity, and, therefore, treatment 
intensity and prognosis. This process could be accom-
plished by a laboratory auto-immunologist [185] well-
trained in recognition of IIF ANA nuclear and, also, 
cytoplasmic patterns, in strict collaboration with the 
clinical doctor, as a decision-maker for running in-
depth analysis towards the identification of the culprit 
autoantibody.
In addition, multicentric studies with a multidisci-
plinary approach may help bridging the divide of the 
selection bias depending on the setting where patients 
are initially screened (i.e. pneumologic vs. dermatologic 
vs. immuno-rheumatologic vs. neurologic outpatient 
clinics).
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